BVF
Not that I care about TheStreet.com's ratings, but for what it's worth...
Don't mind me...just talking to myself.
Biovail (BVF - Cramer's Take - Stockpickr - Rating) engages in the clinical testing, registration, manufacture and commercialization of pharmaceutical products using various drug-delivery technologies. It has been downgraded to a hold from a buy. The company has some strengths and some weaknesses. It has no debt to speak of, profit margins are expanding and it has a quick ratio of 2.10, demonstrating its ability to cover short-term liquidity needs.
As a counter to these strengths, Biovail EPS growth has been feeble, its return on equity has been disappointing and its net income fell 20.5% in the second quarter compared to the same period last year. The stock's price has increased by 13.81% in the past 12 months, despite the company's weak earnings. There is currently no conclusive evidence that warrants the purchase or sale of this stock. Biovail had been rated a buy since December 2006.
